GSK claims Amgen v Sanofi decision “threatens” innovation
29-04-2021
Sanofi and C4X in $493m licensing deal
13-04-2021
HJBC / Shutterstock.com
The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal Circuit, Lantus SoloStar, insulin, IPR, PTAB, medical devices
